Mast Therapeutics (MSTX)

Company Description

Mast Therapeutics is an advanced clinical stage biopharmaceutical company focusing on the development of MST-188 as a potential treatment resolving vaso-occlusive crisis (VOC) in sickle cell disease (SCD) patients.  The company is conducting a Phase III pivotal (EPIC) study and potentially to report top-line results in late 2015.  Should the study outcome be positive and potentially received approval, MST-188 could potentially be the first VOC in SCD therapeutic launch in the U.S. (possibly in 2017).  MST-188 is also in clinical studies (both ongoing and in planning) in other cardiovascular indications, such as acute limb ischemia (ALI) and heart failure.  The company’s second asset, AIR001 has the potential as a treatment in pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF).

Published Reports

MSTX-2017-01-12-Savara merger rev
mstx-2016-11-09-3q16-rev
mstx-2016-09-27-corporate-update-rev
mstx-2016-09-21-epic-failed-rev
MSTX-2016-08-09-2Q16 rev
MSTX-2016-08-01-INDIE-HFpEF P2 Started rev
MSTX-2016-05-17-Positive AIR001 Phase IIa interim data rev
MSTX-2016-05-09-1Q16 rev
MSTX-2016-03-14-4Q15 rev
MSTX-2016-02-01-AIR001 P2 positive rev (1)
MSTX-2016-01-07-Company update rev (1)
MSTX-2015-11-13-3Q15 rev
MSTX-2015-10-27-Chronic heart failure P2 study rev2 (1)
MSTX-2015-03-02-Vepoloxamer in heart failure pre-clinical data
MSTX-2014-10-31-3Q14
MSTX-2015-10-08-Analyst day
MSTX-2015-10-27-Chronic-heart-failure-P2-study-rev2
MSTX-2015-08-13-2Q15 rev
MSTX-2015-05-26-EPIC-E study commenced rev
MSTX-2015-05-11-1Q15 rev
MSTX-2015-04-21-EPIC enrollment update rev2
MSTX-2015-04-09-Vepoloxamer preclinical presentation rev4
MSTX-2015-03-24-4Q14 rev
MSTX-2015-02-11-Vepoloxamer in stroke pre-clinical data rev
MSTX-2015-02-04-AIR001 P2a trial started rev
MSTX-2015-01-06-EPIC update rev
MSTX-2014-09-29-GLYC trial delay rev
MSTX-2014-09-08-PAH top-line data rev2
MSTX-2014-08-11-2Q14
MSTX-2014-08-06-Initiation